A Phase 1 interventional study of PF-07985631 and Placebo in Healthy, sponsored by Pfizer. Terminated at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07985631) for the possible treatment of a kidney disease called IgA nephropathy.
This study is seeking participants who
PF-07985631 or placebo will be given as a small needle injection (in the abdomen, thigh or back of the arm) at the study clinic. Most participants will receive PF-07985631 or placebo one time. Some participants may receive PF-07985631 or placebo twice.
The study will compare the experiences of people receiving PF-07985631 to those of the people who do not. This will help decide if PF-07985631 is safe and effective.
Participants who take PF-07985631 or placebo will take part in this study for about four- four and a half months. During this time, they will stay at the study clinic for 12 to 19 days and will have 7 more study visits at the study clinic.
During study clinic stays and study visits, blood samples will be done and safety reviews completed.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
Participants with ANY of the following abnormalities in clinical laboratory tests at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be subcutaneous (SC)
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Drug: PF-07985631 Experimental Pfizer compound which will be SC Drug: Placebo Placebo which will be SC
Drug: PF-07985631 · Drug: Placebo
Experimental Pfizer compound which will be SC
Placebo which will be SC
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)
Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria
Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Number of Participants With Notable Electrocardiogram (ECG) Values
Time frame: Baseline (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Maximum Observed Plasma Concentration (Cmax) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Time to Reach Maximum Observed Plasma Concentration (Tmax) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Plasma Decay Half-Life (t1/2) as data permit
Time frame: Predose (Day 1) up to 83 days after last dose of study drug (approximately up to 3 months)
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Dec 2025 to primary completion in Jul 2026, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.